Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 28, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Emily Bodnar Reiterated (ACRV) at Strong Buy and Held Target at $20 on, Mar 28th, 2024
Emily Bodnar of HC Wainwright & Co., Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy and Held Target at $20 on, Mar 28th, 2024.
Emily has made no other calls on ACRV in the last 4 months.
There is 1 other peer that has a rating on ACRV. Out of the 1 peers that are also analyzing ACRV, 0 agree with Emily's Rating of Hold.
This is the rating of the analyst that currently disagrees with Emily
- Silvan Tuerkcan of "JMP Securities" Initiated at Buy and Held Target at $14 on, Friday, March 1st, 2024
